A New Hepatitis C Drug After A Decade of Waiting

Dr. Michell Shiffman of Bon Secours' Liver Institute of Virginia

Dr. Michell Shiffman of Bon Secours' Liver Institute of Virginia

The addition of Boceprevir and telaprevir to the current treatment of chronic HCV represents a significant advance in our ability to help patients with this chronic liver disease.  For the first time treatment will cure more patients of HCV than it fails to cure.  Boceprevir and telaprevir will be effective not only in patients who have not been previously treated, but in patients who have failed to be cured during a previous course of peginterferon and ribavirin.  Of greatest importance is that the vast majority of patients will be able to achieve these high rates of cure, in most cases exceeding approaching 70%, even though the duration of therapy is reduced form by 5 months – from 48 to 28 weeks.

Although Boceprevir and telaprevir are great advances and will help many of our patients, the development of these drugs is just the tip of the iceberg when it comes to treating liver diseases.  At least 10 other anti-viral agents like Boceprevir and telaprevir are currently being tested by several pharmaceutical companies.  Many of these medications are being evaluated at the Liver Institute of Virginia and many patients may be eligible and wish to be treated in clinical trials with these new medications.

Dr Shiffman and his staff at the Liver Institute have extensive experience treating patients with chronic HCV.  Dr Shiffman is one of the world’s key opinion leaders on how to best treat chronic HCV and is a consultant to numerous pharmaceutical companies, which are in the process of developing these new and improved treatments for chronic HCV.

+ Learn more about the Liver Institute of Virginia.
+ Find out if you are eligible to participate in a clinical trial.

This entry was posted in Bon Secours News, Bon Secours Specialties, Featured Health News, General News, Health News & Information, Liver Health, Uncategorized and tagged , , , , , , , , , , , , on by .

About Dr.MLShiffman

Dr. Mitchell Shiffman is the Bon Secours expert on liver disease and liver treatments for Virginia. Prior to joining Bon Secours, Dr. Shiffman was a professor of Medicine at Virginia Commonwealth University (VCU) in Richmond, VA. He was the Chief of the Hepatology Section and Medical Director of the Liver Transplant Program at the VCU Medical Center from 1989 until 2009. During his 20 years at the VCU Medical Center Dr. Shiffman built and directed one of the most respected and productive hepatology programs in the United States. Dr. Shiffman is recognized as one of the world’s leaders in the field of Hepatology. His particular area of research is viral hepatitis. He has been involved with and/or directed numerous clinical trials to develop new and better treatments for viral hepatitis B and C. Dr. Shiffman is a regular speaker on the treatment of viral hepatitis, the management of various liver disorders, and issues related to liver transplantation at regional, national and international society meetings. He has published over 200 articles in medical journals related to the treatment of liver diseases and has edited two books on this topic. In addition, he has contributed to various HCV educational resources including an HCV educational kit. Dr. Shiffman is also a widely recognized expert consultant to pharmaceutical companies on the treatment of liver disease. Dr. Shiffman holds a Bachelor of Arts from State University of New York at Buffalo, a Master of Science in physiology from the University of New Mexico School of Medicine in Albuquerque, N.M. and his Doctor of Medicine from State University of New York Upstate Medical Center in Syracuse, N.Y. He completed his internship and residency in internal medicine and fellowship training in gastroenterology and hepatology at the Medical College of Virginia Hospitals in Richmond, VA. Dr. Shiffman is a member of many professional organizations including: the American College of Gastroenterology, American College of Physicians, the American Gastroenterological Association, American Society for the Study of Liver Diseases, American Society of Transplantation, European Association for the Study of the Liver, International Liver Transplantation Society, Richmond Academy of Medicine, Virginia Medical Society and the Virginia Gastrointestinal Society. He was a member of the Board of Trustees with the American College of Gastroenterology from 2003-2009.

One thought on “A New Hepatitis C Drug After A Decade of Waiting

  1. Pingback: Bon Secours 757 Good Health Blog | New Drugs Promise to Transform the Treatment of Hepatitis C

Speak Your Mind